Advancing Science. Improving Connections.

Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids.

Zynerba Pharmaceuticals has been acquired by Harmony Biosciences, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases. For more information on Harmony and the acquisition, please click here. The RECONNECT clinical trial is ongoing and recruitment remains open. Patients, families and healthcare providers can learn more at FragileXhelp.com. Click here

Our People

Focusing on the unmet medical needs of patients with rare disorders and their families

Our Company

Progressing our mission to improve the lives of patients battling certain rare conditions

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

Latest News

10.11

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

10.04

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

09.29

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

09.14

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium